Urothelial carcinoma is a common cancer and patients with metastatic urothelial cancer (mUC) have very poor outcomes. Many mUC patients do not have durable responses to systemic treatment and are exposed to toxic side effects that negatively impact the patient’s quality of life. Identifying novel biomarkers for therapy and selecting the best treatment option for individual mUC patients is therefore critical. Molecular characterization of urothelial carcinoma has revealed subtypes with different genomic, transcriptomic, and clinicopathological characteristics, which might guide therapeutic decisionmaking. Here, we summarize advances on molecular subtyping of urothelial carcinoma in both primary and metastatic disease, and highlight treatment opportunities for each subtype.
Link: Molecular subtypes of metastatic urothelial carcinoma and treatment options – Clinical Laboratory int. (clinlabint.com)
Authors: J. Alberto Nakauma-González1,2,3 PhD and Joost L. Boormans*2 MD, PhD
1 Cancer Computational Biology Center, Erasmus MC Cancer Institute, University Medical Center Rotterdam
2 Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam
3 Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam